Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis a prospective, multinational, randomised, double-blind, active- controlled clinical phase II study. Gastroenterology 124, A379....
【英文名】Mesalazine 【别名】5-氨基水杨酸；艾迪莎；氨水杨酸；美沙拉秦；颇得斯安；5-氨基水 杨醇；5-Aminosalicylic Acid；5-ASA；Asacolitin；Fisalamine；Mesalamine；Pentasa；Pentasa-R；Rowasa 【剂型】1.缓释片：500mg。2.片剂：250mg，400mg，500mg。3.栓剂：1g。 【药理作用】本药为抗溃疡药，通过...
5-氨基水杨酸、艾迪莎、氨水杨酸、美沙拉秦、颇得斯安、5-氨基水杨醇、5-Aminosalicylic Acid、5-ASA、Asacolitin、Fisalamine、Mesalamine、Pentasa、Pentasa-R、Rowasa 药物剂型 1.缓释片:500mg。2.片剂:250mg,400mg,500mg。3.栓剂:1g。 药理作用 ...
Mesalazine (5-Amino-2-hydroxybenzoic Acid, 5-Aminosalicylic Acid, Fisalamine, 5-ASA, Mesalamine, Asacol, Asacolitin, Claversal, Mesasal, Pentasa) 化学名:Mesalazine (5-Amino-2-hydroxybenzoic Acid, 5-Aminosalicylic Acid, Fisalamine, 5-ASA, Mesalamine, Asacol, Asacolitin, Claversal, Mesasal,...
In conclusion, spot (Nac-)5-ASA urinalysis is not applicable to assess 5-ASA adherence in daily IBD care.doi:10.1111/bcp.13462R?mkens, Tessa E.H.te Morsche, RenePeters, WilbertBurger, David M.Hoentjen, FrankDrenth, Joost P.H.
Background: 5-Aminosalicylic acid (5-ASA) is known to be effective in the treatment of active ulcerative colitis (UC). The aim of the current study was to investigate the effect of 5-ASA enemas, as a maintenance therapy for UC, when administered twice weekly as a weekend treatment regimen...
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005 May; 11(5): 421–7 CrossRef Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately ...
Definition 5-Aminosalicylic acid (5-ASA) has long-term clinical experience in the treatment of patients with inflammatory bowel disease (IBD), is well tolerated, has limited systemic side effects, and has no gastrointestinal toxicity. In a rodent model of colorectal cancer, mesalazine inhibits ...
Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003; 17: 395–402Brunner M, Assandri R, Kletter K, et al.: Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation . Aliment Pharmacol Ther ...
Mesalazine (5-ASA) is a cyclo-oxygenase inhibitor and anti-inflammatory drug effective in Crohn's disease and ulcerative-colitis. As 5-ASA is rapidly absorbed from the small intestine and it is necessary to develop a colon-specific delivery system for it. Coated chitosan microspheres were used ...